Abstract: This invention relates generally to compositions for making C A Vectors and uses thereof.

Abstract: This invention relates generally to compositions for making anellovectors and uses thereof. For instance, the disclosure provides compositions and methods for using insect cells to produce Anellovirus proteins, e.g., ORF1.

Abstract: This invention relates generally to anellosomes and compositions and uses thereof.

Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

Abstract: This invention relates generally to anellosomes and compositions and uses thereof.

Abstract: This invention relates generally to anellosomes and compositions and uses thereof.

Abstract: This invention relates generally to anellosomes and compositions and uses thereof.

Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.

Abstract: A terminal box for a generator set is disclosed. The terminal box may include a generally open structural member configured to be mounted to a generator barrel of the generator set. The structural member may have a first end and a second end that is wider than the first end. When the structural member is mounted to the generator barrel in a first orientation, the second end may be located at a first position relative to the generator set. When the structural member is mounted to the generator barrel in a second orientation, the second end may be located at a second position relative to the generator set.

Abstract: A terminal box for a generator set is disclosed. The terminal box may include a generally open structural member configured to be mounted to a generator barrel of the generator set. The structural member may have a first end and a second end that is wider than the first end. When the structural member is mounted to the generator barrel in a first orientation, the second end may be located at a first position relative to the generator set. When the structural member is mounted to the generator barrel in a second orientation, the second end may be located at a second position relative to the generator set.

Abstract: Pressure sensitive devices, systems and methods for alerting a user of movements potentially adverse to health or surgical recovery are disclosed. The pressure sensitive device may include a force sensor placed along the anterior aspect of a hand; and a vibration motor in communication with the force sensor in close proximity to the user, e.g., along the posterior aspect of the wrist. The vibration motor is configured to vibrate upon the measured force exceeding a predetermined threshold. This threshold can be adjusted according to clinical application and/or user need. The pressure sensitive device may further include a memory chip or wireless transmitter for recording and relaying data associated with a patient profile, and is enabled to interface with a Wi-Fi sensing technology. Logged data may be used for patient rehabilitation.

Abstract: A sewer flushing device 20 for location in a sewage system. The device comprises a housing 21 adapted for location in a sewage flow path 14 and a gate 22 pivotally supported on the housing 21 and movable between open and closed positions. The gate is biased towards its closed position so as to inhibit the flow of sewage and thereby cause a build up of sewage. In this way, when the sewage upstream of the gate 22 reaches a predetermined level the gate is urged to its open position such that a flushing pulse of sewage flows downstream. There may also be provided a locating device 23 for holding the housing 21 in the required position within the sewage system. The locating device may comprise a sewer engaging portion 51,52 adapted to locate in a sewer channel 12,14, and a housing connector 54 adapted to connect to the housing 21.

Abstract: A sewer flushing device 20 for location in a sewage system. The device comprises a housing 21 adapted for location in a sewage flow path 14 and a gate 22 pivotally supported on the housing 21 and movable between open and closed positions. The gate is biased towards its closed position so as to inhibit the flow of sewage and thereby cause a build up of sewage. In this way, when the sewage upstream of the gate 22 reaches a predetermined level the gate is urged to its open position such that a flushing pulse of sewage flows downstream. There may also be provided a locating device 23 for holding the housing 21 in the required position within the sewage system. The locating device may comprise a sewer engaging portion 51,52 adapted to locate in a sewer channel 12,14, and a housing connector 54 adapted to connect to the housing 21.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier.

Abstract: A grille system comprising at least two rod arrangements 1a and at least one clamping member 12. The clamping member 12 retains the rod arrangements b 1a in a predetermined spacial configuration. Each rod arrangement 1a comprises a straight rod 2 having a first end portion 2a provided with an expanded portion 3 received by the clamping member 12. The clamping member 12 comprises two separate, corresponding portions 5 secured together by a bolt 10 and nut 11. The grille system is used as a security grille or in the manufacture of garden furniture or plant supports.